|
1
|
Yakob M, Fuentes L, Wang MB, Abemayor E
and Wong DT: Salivary biomarkers for detection of oral squamous
cell carcinoma - current state and recent advances. Curr Oral
Health Rep. 1:133–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Exarchos KP, Goletsis Y and Fotiadis DI: A
multiscale and multiparametric approach for modeling the
progression of oral cancer. BMC Med Inform Decis Mak. 12:1362012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
5
|
Tseng CH: Oral cancer in Taiwan: Is
diabetes a risk factor? Clin Oral Investig. 17:1357–1364. 2013.
View Article : Google Scholar
|
|
6
|
The Oral Cancer Foundation. Oral Cancer
Facts. Website. http://www.oralcancerfoundation.org/facts/.
Access date: February 28, 2016
|
|
7
|
Rivera C: Essentials of oral cancer. Int J
Clin Exp Pathol. 8:11884–11894. 2015.PubMed/NCBI
|
|
8
|
Zini A, Czerninski R and Sgan-Cohen HD:
Oral cancer over four decades: Epidemiology, trends, histology, and
survival by anatomical sites. J Oral Pathol Med. 39:299–305. 2010.
View Article : Google Scholar
|
|
9
|
Inagi K, Takahashi H, Okamoto M, Nakayama
M, Makoshi T and Nagai H: Treatment effects in patients with
squamous cell carcinoma of the oral cavity. Acta Otolaryngol
(Suppl). 547:25–29. 2002. View Article : Google Scholar
|
|
10
|
Shingaki S, Takada M, Sasai K, Bibi R,
Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis
on the pattern of failure and survival in oral carcinomas. Am J
Surg. 185:278–284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ogawa T, Washio J, Takahashi T, Echigo S
and Takahashi N: Glucose and glutamine metabolism in oral squamous
cell carcinoma: Insight from a quantitative metabolomic approach.
Oral Surg Oral Med Oral Pathol Oral Radiol. 118:218–225. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng
L, Bhalla KN, Keating MJ and Huang P: Inhibition of glycolysis in
cancer cells: A novel strategy to overcome drug resistance
associated with mitochondrial respiratory defect and hypoxia.
Cancer Res. 65:613–621. 2005.PubMed/NCBI
|
|
14
|
Feron O: Pyruvate into lactate and back:
From the Warburg effect to symbiotic energy fuel exchange in cancer
cells. Radiother Oncol. 92:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Courtnay R, Ngo DC, Malik N, Ververis K,
Tortorella SM and Karagiannis TC: Cancer metabolism and the Warburg
effect: The role of HIF-1 and PI3K. Mol Biol Rep. 42:841–851. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Faubert B, Boily G, Izreig S, Griss T,
Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et
al: AMPK is a negative regulator of the Warburg effect and
suppresses tumor growth in vivo. Cell Metab. 17:113–124. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ
and Dennis PA: Repositioning metformin for cancer prevention and
treatment. Trends Endocrinol Metab. 24:469–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rêgo DF, Pavan LM, Elias ST, De Luca Canto
G and Guerra EN: Effects of metformin on head and neck cancer: A
systematic review. Oral Oncol. 51:416–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tseng CH: Metformin reduces thyroid cancer
risk in Taiwanese patients with type 2 diabetes. PLoS One.
9:e1098522014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tseng CH: Metformin may reduce bladder
cancer risk in Taiwanese patients with type 2 diabetes. Acta
Diabetol. 51:295–303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tseng CH: Diabetes, metformin use, and
colon cancer: A population-based cohort study in Taiwan. Eur J
Endocrinol. 167:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tseng CH: Metformin significantly reduces
incident prostate cancer risk in Taiwanese men with type 2 diabetes
mellitus. Eur J Cancer. 50:2831–2837. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tseng CH: Metformin may reduce breast
cancer risk in Taiwanese women with type 2 diabetes. Breast Cancer
Res Treat. 145:785–790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tseng CH: Metformin and endometrial cancer
risk in Chinese women with type 2 diabetes mellitus in Taiwan.
Gynecol Oncol. 138:147–153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tseng CH: Metformin reduces ovarian cancer
risk in Taiwanese women with type 2 diabetes mellitus. Diabetes
Metab Res Rev. 31:619–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tseng CH: Metformin may reduce oral cancer
risk in patients with type 2 diabetes. Oncotarget. 7:2000–2008.
2016.
|
|
28
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen G, Xu S, Renko K and Derwahl M:
Metformin inhibits growth of thyroid carcinoma cells, suppresses
self-renewal of derived cancer stem cells, and potentiates the
effect of chemotherapeutic agents. J Clin Endocrinol Metab.
97:E510–E520. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ling S, Feng T, Ke Q, Fan N, Li L, Li Z,
Dong C, Wang C, Xu F, Li Y, et al: Metformin inhibits proliferation
and enhances chemosensitivity of intrahepatic cholangiocarcinoma
cell lines. Oncol Rep. 31:2611–2618. 2014.PubMed/NCBI
|
|
31
|
Honjo S, Ajani JA, Scott AW, Chen Q,
Skinner HD, Stroehlein J, Johnson RL and Song S: Metformin
sensitizes chemotherapy by targeting cancer stem cells and the mTOR
pathway in esophageal cancer. Int J Oncol. 45:567–574.
2014.PubMed/NCBI
|
|
32
|
Wu X, He C, Wu Y and Chen X: Synergistic
therapeutic effects of Schiff's base cross-linked injectable
hydrogels for local co-delivery of metformin and 5-fluorouracil in
a mouse colon carcinoma model. Biomaterials. 75:148–162. 2016.
View Article : Google Scholar
|
|
33
|
Zhao Q, Wang J, Zou MJ, Hu R, Zhao L,
Qiang L, Rong JJ, You QD and Guo QL: Wogonin potentiates the
antitumor effects of low dose 5-fluorouracil against gastric cancer
through induction of apoptosis by down-regulation of NF-kappaB and
regulation of its metabolism. Toxicol Lett. 197:201–210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nicolucci A: Epidemiological aspects of
neoplasms in diabetes. Acta Diabetol. 47:87–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar
|
|
37
|
Rizos CV and Elisaf MS: Metformin and
cancer. Eur J Pharmacol. 705:96–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Currie CJ, Poole CD, Jenkins-Jones S, Gale
EA, Johnson JA and Morgan CL: Mortality after incident cancer in
people with and without type 2 diabetes: Impact of metformin on
survival. Diabetes Care. 35:299–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar :
|
|
40
|
Ruiter R, Visser LE, van Herk-Sukel MP,
Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings
RM and Stricker BH: Lower risk of cancer in patients on metformin
in comparison with those on sulfonylurea derivatives: Results from
a large population-based follow-up study. Diabetes Care.
35:119–124. 2012. View Article : Google Scholar :
|
|
41
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nair V, Pathi S, Jutooru I, Sreevalsan S,
Basha R, Abdelrahim M, Samudio I and Safe S: Metformin inhibits
pancreatic cancer cell and tumor growth and downregulates Sp
transcription factors. Carcinogenesis. 34:2870–2879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Akinyeke T, Matsumura S, Wang X, Wu Y,
Schalfer ED, Saxena A, Yan W, Logan SK and Li X: Metformin targets
c-MYC oncogene to prevent prostate cancer. Carcinogenesis.
34:2823–2832. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The anti-diabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Petrushev B, Tomuleasa C, Soritau O, Aldea
M, Pop T, Susman S, Kacso G, Berindan I, Irimie A and Cristea V:
Metformin plus PIAF combination chemotherapy for hepatocellular
carcinoma. Exp Oncol. 34:17–24. 2012.PubMed/NCBI
|
|
47
|
Viollet B, Guigas B, Sanz Garcia N,
Leclerc J, Foretz M and Andreelli F: Cellular and molecular
mechanisms of metformin: An overview. Clin Sci (Lond). 122:253–270.
2012. View Article : Google Scholar
|
|
48
|
Martin-Castillo B, Vazquez-Martin A,
Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses,
mechanisms and the dandelion and hormetic phenomena. Cell Cycle.
9:1057–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tseng CH: Pioglitazone and oral cancer
risk in patients with type 2 diabetes. Oral Oncol. 50:98–103. 2014.
View Article : Google Scholar
|
|
50
|
Takiyama Y, Harumi T, Watanabe J, Fujita
Y, Honjo J, Shimizu N, Makino Y and Haneda M: Tubular injury in a
rat model of type 2 diabetes is prevented by metformin: A possible
role of HIF-1α expression and oxygen metabolism. Diabetes.
60:981–992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tanaka R, Tomosugi M, Horinaka M, Sowa Y
and Sakai T: Metformin causes G1-phase arrest via down-regulation
of MiR-221 and enhances TRAIL sensitivity through DR5 up-regulation
in pancreatic cancer cells. PLoS One. 10:e01257792015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ashinuma H, Takiguchi Y, Kitazono S,
Kitazono-Saitoh M, Kitamura A, Chiba T, Tada Y, Kurosu K, Sakaida
E, Sekine I, et al: Antiproliferative action of metformin in human
lung cancer cell lines. Oncol Rep. 28:8–14. 2012.PubMed/NCBI
|
